MANNKIND CORP Proceeds from Lines of Credit
MANNKIND CORP (MNKD) reported Proceeds from Lines of Credit of $10.00 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2023-02-23
- MANNKIND CORP proceeds from lines of credit for the quarter ending 2019-12-31 was $0.00.
- MANNKIND CORP proceeds from lines of credit for fiscal 2020 was $10.00M, a 75.00% decline from fiscal 2019.
- MANNKIND CORP proceeds from lines of credit for fiscal 2019 was $40.00M.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|
| 2020-12-31 | $10.00M 10-K · filed 2023-02-23 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $40.00M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $40.00M 10-Q · filed 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |